Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post-COVID Syndrome.

Background: Post-coronavirus disease 2019 syndrome (PCS) is characterized by persistent symptoms lasting >12 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The underlying pathological mechanisms remain poorly understood.

Methods: We conducted detailed immunological analyses in 47 individuals with PCS, assessed >12 weeks after acute SARS-CoV-2 infection, and we compared them with 25 convalescent controls without symptoms.

Early treatment and PD1 inhibition enhance HIV-specific functionality of follicular CD8+ T cells.

People living with HIV treated during acute infection are the group for whom achieving functional cure appears most viable. Follicular CD8+ T cells could contribute to HIV reservoir clearance by accessing B cell follicles through CXCR5 expression. This study examines peripheral follicular CD8+ T cells using flow cytometry, transcriptome analyses, and functional assays in people treated during acute (n = 37) and chronic (n = 18) infection, as well as in individuals naturally controlling HIV (n = 20) and living without HIV (n = 10).

[Lymphadenopathy - infection or malignancy?].

A persistent lymphadenopathy poses a diagnostic challenge for physicians. A wide variety of different diseases can manifest with enlarged lymph nodes. The most common causes are infections and other non-malignant conditions, but it is important not to overlook warning signs of a malignant disease to avoid delaying further diagnostics and therapy.

Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.

Background: Doravirine/islatravir is an investigational, once-daily regimen being studied for HIV-1 treatment.

Methods: In this phase 3, double-blind, non-inferiority trial, previously untreated people with HIV-1 (≥18 years) were randomized (1:1) and stratified by HIV-1 RNA (≤/>100,000 copies/mL) and CD4 count ( View Article and Find Full Text PDF

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Background: Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance. We investigated a switch from bictegravir, emtricitabine, and tenofovir alafenamide to doravirine (100 mg) and islatravir (0·75 mg) in virologically suppressed adults with HIV-1.

Methods: We conducted a phase 3, multicentre, randomised, active-controlled, double-blind, double-dummy, non-inferiority trial at 89 research, community, and hospital-based clinics in 11 countries.